Search Medical Condition
Please enter condition
Please choose location

Bernau, Germany Clinical Trials

A listing of Bernau, Germany clinical trials actively recruiting patients volunteers.

RESULTS

Found (81) clinical trials

BAROSTIM THERAPY in Heart Failure With Reduced Ejection Fraction

The purpose of this registry is to evaluate the effect of BAROSTIM THERAPY with the BAROSTIM NEO System in the commercial setting in subjects recently implanted under the CE-Marked indication for heart failure with reduced ejection fraction (HFrEF).

Phase N/A

0.0 miles

Learn More »

BAROSTIM THERAPY In Resistant Hypertension

The purpose of this registry is to evaluate the effect of BAROSTIM THERAPY with the BAROSTIM NEO System in the commercial setting in subjects recently implanted under the CE-Marked indication for resistant hypertension.

Phase N/A

0.0 miles

Learn More »

Absorb IV Randomized Controlled Trial

ABSORB IV: A. Primary Objective: - To evaluate 1-year clinical outcomes of the Absorb BVS compared to XIENCE in the treatment of subjects with ischemic heart disease caused by up to three de novo native coronary artery lesions in a maximum of two epicardial vessels, with a maximum of two ...

Phase N/A

0.0 miles

Learn More »

AdaptResponse Clinical Trial

The purpose of this clinical study is to test the hypothesis that market released Cardiac Resynchronization Therapy (CRT) devices which contain the AdaptivCRT (aCRT) algorithm have a superior outcome compared to standard CRT devices in CRT indicated patients with normal atrio-ventricular (AV) conduction and left bundle branch block (LBBB).

Phase N/A

0.0 miles

Learn More »

Sentus QP - Extended CRT Evaluation With Quadripolar Left Ventricular Leads

The QP ExCELs study is designed to confirm safety and efficacy of the BIOTRONIK Sentus OTW QP left ventricular leads to satisfy FDA requirements for regulatory approval of the leads in the US. The Sentus OTW QP leads received FDA approval on May 4, 2017. Long-term safety of the BIOTRONIK ...

Phase N/A

0.0 miles

Learn More »

Neuroregeneration Enhanced by Transcranial Direct Current Stimulation (TDCS) in Stroke

Stroke is the leading cause of long-term disability, which significantly impairs the economic and social life of patients and society. Every year 200 000 to 250 000 patients suffer a stroke in Germany. Only a small number of the stroke survivors recover to a degree that allows them to return ...

Phase N/A

0.0 miles

Learn More »

A Study of Percutaneous Treatment of Mitral Regurgitation Using the AccuCinch System

Prospective single-arm study of the AccuCinch Ventriculoplasty System in the treatment of mitral valve regurgitation through subvalvular mitral repair. Purpose: To demonstrate the safety, feasibility and potential efficacy of using the AccuCinch Ventriculoplasty System to reduce mitral valve regurgitation through subvalvular mitral repair.

Phase N/A

0.0 miles

Learn More »

BAROSTIM THERAPY In Heart Failure With Preserved Ejection Fraction

The purpose of this registry is to evaluate the effect of BAROSTIM THERAPY with the BAROSTIM NEO system in the commercial setting in subjects recently implanted under the CE-Marked indication for resistant hypertension that also have evidence of heart failure with preserved ejection fraction (HFpEF).

Phase N/A

0.0 miles

Learn More »

Basel Stent Kosten Effektivit ts Trial Drug Eluting Balloons vs. Drug Eluting Stents in Small Vessel Interventions

Drug-eluting balloons are an established treatment for in-stent stenoses and showed good results in small vessels. Moreover, the available data suggest that DEB are a promising new technique for the treatment of de-novo stenoses in small vessels if pre-dilatation is performed and geographical mismatch is avoided. The aim of this ...

Phase N/A

0.0 miles

Learn More »

BIO|MASTER.Edora Family Study

Study Design Open-label, prospective, non-randomized, multicenter, international about 13 study sites Study Endpoints The following endpoints are defined and will be assessed with descriptive analysis: AV Opt feature: The feature's AV delay recommendation was used as basis for the device programming or is at least considered to be clinically acceptable ...

Phase N/A

0.0 miles

Learn More »